Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02222922 · ClinicalTrials.gov registry record · Phase 1

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

A Phase 1 study of Neoplasms, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
138
Enrollment target
17
Study locations

NCT02222922 is a Phase 1 study of Neoplasms that has completed, run by Pfizer. The registered enrollment target is 138 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The trial reports 17 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02222922, a Phase 1 study of Neoplasms, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
138 participants
Enrollment target
17
Study locations

Study Summary

To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Conditions Studied

Neoplasms

Interventions

  • DRUG fluconazole
  • DRUG PF-06647020 Q3W
  • DRUG PF-06647020 Q2W
  • DRUG PF-06647020 combined with Avelumab

Study Locations (17)

Virginia

  • Inova Fairfax Hospital Woodburn GYN Infusion Center - Annandale
  • Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates (MAGOPSA) - Annandale
  • Fairfax Radiological Consultants - Fairfax
  • Inova Schar Cancer Institute - Fairfax
  • Inova Loudon Hospital - Leesburg

California

  • University of California Davis Comprehensive Cancer Center - Sacramento
  • University of California Davis Medical Center - Sacramento
  • Stanford Cancer Center - Stanford
  • Stanford Hospital and Clinics - Stanford

Alabama

  • University of Alabama at Birmingham - Birmingham
  • University of Alabama at Birmingham - Birmingham

Other

  • Hospital Universitario Fundacion Jimenez Diaz - Madrid
  • Hospital Universitario Madrid Sanchinarro - Madrid

Arizona

  • Scottsdale Healthcare Hospitals DBA HonorHealth - Scottsdale

Illinois

  • University of Chicago Medicine - Chicago

Michigan

  • START Midwest - Grand Rapids

Texas

  • South Texas Accelerated Research Therapeutics, LLC - San Antonio

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2014-10-17
Est. Completion 2019-11-05
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02222922

The ClinicalTrials.gov registry entry for NCT02222922 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which fluconazole is the first listed.

NCT02222922 reports 17 study locations spanning 8 distinct geographic areas - top geographies include Virginia, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT02222922 about?

NCT02222922 is a clinical study titled "A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors". To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

What is the current status of trial NCT02222922?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2014-10-17. Estimated completion is 2019-11-05.

What conditions does trial NCT02222922 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT02222922?

The interventions under investigation include: fluconazole (DRUG), PF-06647020 Q3W (DRUG), PF-06647020 Q2W (DRUG), PF-06647020 combined with Avelumab (DRUG).

Who is sponsoring clinical trial NCT02222922?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02222922 being conducted?

This trial has 17 study locations across Alabama, Arizona, California, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.